A large and  
growing market

Addressing 2 leading causes of blindness for ~1 million patients

Glaucoma and cataracts are the 2 leading causes of blindness worldwide—and frequently coexist in the same patients. In the United States alone, approximately 1 million glaucoma and ocular hypertension (OHT) patients are expected to undergo cataract surgery in 2025.¹

3% to 4%

Projected year-over-year growth  in cataract surgery volumes

A growing patient opportunity

The number of cataract procedures performed in the US is expected to increase by 3% to 4% per year.²

By embedding glaucoma therapy directly into the cataract surgery workflow, SpyGlass aims to transform an existing, high-volume procedure into an opportunity for long-term IOP control—without requiring new techniques, devices, or infrastructure.³

A large and growing market

Addressing 2 leading causes of blindness for ~1 million patients

A growing patient opportunity

By embedding glaucoma therapy directly into the cataract surgery workflow, SpyGlass aims to transform an existing, high-volume procedure into an opportunity for long-term IOP control—without requiring new techniques, devices, or infrastructure.3

See the evidence behind this opportunity.

Please confirm you wish to leave SpyGlassPharma.com

Please confirm you wish to open the SpyGlass LinkedIn page in another window.

A large and  
growing market

By embedding glaucoma therapy directly into the cataract surgery workflow, SpyGlass aims to transform an existing, high-volume procedure into an opportunity for long-term IOP control—without requiring new techniques, devices, or infrastructure.³

Please confirm you wish to leave
SpyGlassPharma.com